Burning Rock Biotech Ltd.

Foundation year

2014

Open price

$16.50

Close date

6/16/2020

Close price

$24.20

Profitability

46.67%

About

Total Funding

$193.2M


Burning Rock focuses on providing individualized cancer treatment guidance for the patients. Using medical and bio informatics plus Next-Generation Sequencing (NGS) as the core technologies, the company is committed to offering one-stop solution for clinical and R&D services concerning the genetic testing of individualized cancer treatment. Established in March 2014, Burning Rock is headquartered in Beijing. Its first medical laboratory, "Guangzhou Burning Rock Medical Examination Institute Co., Ltd." is situated on Guangzhou International Bio Island which is blessed with a picturesque environment and rich in scientific research deposits. Later it established a R&D center in Shanghai. It occupies over 10,000 ㎡ in total. Burning Rock is committed to guiding the individualistic treatment of tumor patients, centered around NGS and biomedical informatics, with conventional tumor molecular pathology detection as the cornerstone, trying to build one-stop solutions for individualistic treatment clinical detection service and scientific research of tumor.

Other companies


2022 © All rights reserved

You can always come to our office to discuss any questions with our manager

Dubai

Sharjah Media City, Sharjah, UAE

USA

500 Delaware ave,
STE 1 #1960 Wilmington, DE, USA

Czech Republic

Czech Republic, Prague, Bilkova 855/19

The investment opportunities posted on this website's Pre-IPO section are private placements of securities that are not traded on the open market, subject to the ownership period requirements, and intended for investors who do not require liquid investments. Investments in private companies may be considered speculative, involving high risk, including the significant loss of investment risk. Investors must be able to afford to lose all their investments.